Abstract
Screening of a non-ionizable compound library and hit optimization studies has resulted in a series of compounds based on a 4-arylmethyl-3-(4-carboxyphenyl)-5-hydroxyisoxazole scaffold with GCP II inhibitory activity in the low micromolar range.
Keywords: Glutamate carboxypeptidase II, Glutamate, 5-hydroxyisoxazole, Lipophilicity, Synthesis
Letters in Drug Design & Discovery
Title: Identification of GCP II Inhibitors Based on 4-Arylmethyl-3-(4- carboxyphenyl)-5-hydroxyisoxazole Scaffold
Volume: 6 Issue: 1
Author(s): M. Teus, A. Jirgensons, M. Dambrova, R. Mezhapuke, C. G. Parsons and W. Danysz
Affiliation:
Keywords: Glutamate carboxypeptidase II, Glutamate, 5-hydroxyisoxazole, Lipophilicity, Synthesis
Abstract: Screening of a non-ionizable compound library and hit optimization studies has resulted in a series of compounds based on a 4-arylmethyl-3-(4-carboxyphenyl)-5-hydroxyisoxazole scaffold with GCP II inhibitory activity in the low micromolar range.
Export Options
About this article
Cite this article as:
Teus M., Jirgensons A., Dambrova M., Mezhapuke R., Parsons G. C. and Danysz W., Identification of GCP II Inhibitors Based on 4-Arylmethyl-3-(4- carboxyphenyl)-5-hydroxyisoxazole Scaffold, Letters in Drug Design & Discovery 2009; 6 (1) . https://dx.doi.org/10.2174/157018009787158544
DOI https://dx.doi.org/10.2174/157018009787158544 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Editorial [Hot Topic: Diabetic Neuropathy (Guest Editor: Eva L. Feldman)]
Current Drug Targets Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetic Retinopathy: Mechanistic Insights into High Glucose-Induced Retinal Cell Death
Current Clinical Pharmacology The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Nutraceutical Approach to Peripheral Neuropathies: Evidence from Clinical Trials
Current Drug Metabolism Towards Understanding the Structure-Function Relationship of Human Amyloid Disease
Current Drug Targets Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Plant- and Nutraceutical-based Approach for the Management of Diabetes and its Neurological Complications: A Narrative Review
Current Pharmaceutical Design Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Bioartificial Pancreas: Drug Delivery through Islet Microencapsulation to Treat Diabetes
Recent Patents on Biomedical Engineering (Discontinued) Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Autologous Circulating Progenitor Cells Transplanted with Hybrid Scaffold Accelerate Diabetic Wound Healing in Rabbit Model
Current Tissue Engineering (Discontinued) Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews Opioids in Neuropathic Pain
Current Pharmaceutical Design Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued)